Get the Stockscreener App
5.14
0.96%
-0.05
After Hours:
5.12
-0.02
-0.39%
Immuneering Corp stock is traded at $5.14, with a volume of 834.30K.
It is down -0.96% in the last 24 hours and up +20.37% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$5.19
Open:
$5.2
24h Volume:
834.30K
Relative Volume:
0.58
Market Cap:
$332.54M
Revenue:
$500
Net Income/Loss:
$-54.44M
P/E Ratio:
-4.409
EPS:
-1.1658
Net Cash Flow:
$-49.91M
1W Performance:
+1.78%
1M Performance:
+20.37%
6M Performance:
-23.51%
1Y Performance:
+48.99%
1-Day Range:
$5.11
$5.301
1-Week Range:
$4.84
$5.301
52-Week Range:
$2.90
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.14 | 322.84M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX) - TradingView
IMRX Forecast — Price Target — Prediction for 2027 - TradingView
Immuneering CEO Zeskind buys $10,948 in stock - Investing.com UK
Form 4 Immuneering Corp For: 24 June By Investing.com - Investing.com Canada
Immuneering CEO Zeskind buys $10,948 in stock By Investing.com - Investing.com Canada
Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading - Stock Titan
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant - Stock Titan
Immuneering names Andrew Gengos as CFO - MSN
Immuneering names Andrew Gengos as chief financial officer - Investing.com
Immuneering Appoints Andrew Gengos as Chief Financial Officer - The Manila Times
Immuneering names Andrew Gengos as chief financial officer By Investing.com - Investing.com Canada
IMRX begins dosing in phase III pancreatic cancer study, stock up - MSN
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026 - Minichart
Immuneering doses first patient in phase 3 pancreatic cancer trial - Investing.com
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - The Manila Times
Immuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
Uprising in pancreatic space more than Revolution - BioWorld News
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Mizuho reiterates Immuneering stock rating after trial data update - Investing.com
Immuneering Corporation 8-K SEC Filing: Company Information, NASDAQ Listing, and Compliance Details (June 1, 2026) - Minichart
According to a document submitted to the U.S. Securities and Exchange Commission, as of April 24, 2026, biotechnology company Immuneering Corp observed a median overall survival of 17.3 months in the intent-to-treat population of its 320 mg dosage gro - Bitget
[8-K] Immuneering Corp Reports Material Event - Stock Titan
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering stock maintained at Outperform by Oppenheimer on survival data - Investing.com South Africa
Immuneering reports median survival data from pancreatic trial - Investing.com
Immuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with Atebimetinib - Quiver Quantitative
Pancreatic cancer drug combo shows 17.3-month survival in trial - Stock Titan
Immuneering Corp stock (US45255L1089): IMRX trades around 5.36 USD ahead of key June data - AD HOC NEWS
IMRXImmuneering Corp Stock Price and Quote - Finviz
Immuneering Corporation (IMRX) Slides 2.2% as Pressure Mounts Near Key SupportBreakout Stock Alerts - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentCFO Commentary Report - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower Loss Exceeds Expectations as Pipeline Progress ContinuesPre-Announcement Alert - newsline.com
ASCO to spotlight pancreatic cancer innovation beyond KRAS - BioCentury
MEK inhibitor delivers 17.3-month OS for pancreatic cancer - BioWorld News
IMRX Jumps As Immuneering Touts Atebimetinib Pipeline Momentum - timothysykes.com
Immuneering reports 17.3-month survival in pancreatic cancer trial - Investing.com
Immuneering stock jumps on pancreatic cancer trial data By Investing.com - Investing.com Nigeria
Immuneering stock jumps on pancreatic cancer trial data - Investing.com
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immuneering Corp Stock (IMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 15 '26 |
Buy |
4.15 |
6,035 |
25,045 |
382,531 |
| Brakewood Harold Eugene | Chief Business Officer |
Jan 16 '26 |
Buy |
4.76 |
5,250 |
24,990 |
11,050 |
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):